---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-110878"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T20:02:32.757911+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Emmaus Q3 net loss $2.1M; revenue down 38% YoY to $3.4M on generic competition

## Summary
- Net loss of $2.1M ($0.03/share) vs net income of $1.8M in Q3 2024.
- Revenue fell 38% to $3.4M from $5.5M; decline driven by generic L-Glutamine in U.S. and lower MENA sales.
- Operating expenses reduced 43% to $2.4M due to workforce reduction and cost cuts.
- Income from operations $0.7M vs $0.8M prior year, partially offsetting revenue drop.
- Cash and equivalents dropped to $0.3M at Sept 30 from $1.4M at Dec 31, 2024.

## SEC filing metadata
- accession: 0001213900-25-110878
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390025110878/0001213900-25-110878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390025110878/ea0265516-8k_emmaus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-110878
- JSON: https://secwatch.observer/filing/0001213900-25-110878.json
- Plain text: https://secwatch.observer/filing/0001213900-25-110878.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.